ABSTRACT
Almost every person has taken one or other drug in his life. Drugs are well known to cause adverse effects as a collateral or side effect. Talking more than one drugs for single disease or coexistent diseases, taking a drug for a long time for chronic diseases, presence of comorbidities (malnutrition, anaemia, worm infestation etc) and use of alternative systems of medicine (homeopathy, ayurveda, yoga, sidha etc) further increases the risk of developing unforeseeable adverse events and adverse drug reactions (ADR). [1] An 'adverse event' is defined as any untoward medical occurrences that may present during treatment with a drug, but which does not necessarily have a causal relationship with its use. [2] An 'adverse drug reaction' is a noxious, unintended and undesirable effect of a drug, occurring at a does recommended in acceptable medical practice for prophylaxis, diagnosis, therapy or modification of physiological functions [3] and results in:
 A change in drug therapy including change in dosage or discontinuation of therapy.  Initial or prolonged hospitalization  Intervention supportive treatment to prevent permanent impairment or damage  A life threatening event  Permanent disability  Death  Congenital anomaly ADR also includes all reactions to new drugs i.e. drugs in the market for 3 years or less. There are many types of adverse drug reactions: 
Need for Pharmacovigilance
In a vast country like India, with more than 1 billion population, the health needs are vast. Pharmaceutical industry has grown and flourished over time and at present India is the fourth largest producer of pharmaceuticals in world. Although a new drug is marketed only after undergoing a variety of preclinical and clinical tests in experimental animals and human beings during various phases of development. But, this is not enough, as premarketing frequencies of ADRs are based on clinical trials carried out on a 'select study population' for a limited period of time. Therefore Safety data generated from these trials fails to identify infrequent and late onset adverse drug reactions. Moreover when a new drug is marketed minimal or no information is available regarding its safety in special groups like children, elderly patients, pregnant and lactating females. Several new drugs are being launched in Indian market almost simultaneously as in worlds market. Hence post marketing safety data (which is a better overall reflection of adverse effects in general population) is not at all available at the time of introduction of a new drug in market. [4] If the postmarketting monitoring and reviewing process is absent, the pharmacological effects of drugs, their adverse effects, interaction and misuse threaten to play havoc with the health system of the country. Hence identifying 'signals' of drug safety problems as early as possible is of utmost importance. A 'signal' is the 'reported information' on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously. Detection of ADRs requires the vigilance of all health care professionals. In other words a vibrant Pharmacovigilance system is needed to protect the population from potential harm that may be caused by these new drugs.
According to WHO 'Pharmacovigilance' refers to the science and activity relating to the detection, assessment, understanding and prevention of adverse effects or any other drug related problems. It includes identification of side effects of drugs, their treatment, documentation, reporting and regulatory decisions based on them.
National Pharmacovigilance program
The Central drug standard control organization (CDSCO) launched a highly participative 'National Pharmacovigilance programme' in November 2004, with the aim of collecting, analyzing and archiving ADR data for making regulatory decisions regarding drugs marketed in India. It promises to maintain a close watch over the use of drugs and their effects on people. The immediate objective is to foster a culture of notification of ADRs among doctors as well as other health care providers viz pharmacists and nurses and the long term objective is to generate ADR data. [5] In order to have a viable ADR data capturing system, the National Pharmacovigilance program is structured and 2 zonal Pharmacovigilance program is structured as a three tier system. It consists of 24 peripheral, 5 regional and 2 zonal pharmacological centers. At the apex is National Pharmacovigilance advisory committee and National Pharmacovigilance center based at CDSCO, New Delhi. Spontaneous reporting of adverse events and drug reactions by health care seems to be the most suitable method for generating safety data. [6] Practicing physicians should report (on suspected adverse drug reaction reporting from published by CDSCO) observed adverse events and ADRs to peripheral centers (established in teaching and non teaching hospitals, clinics and pharmacies) which forward the received information to its respective regional center on weekly basis. It maintains patients confidentially.
Reporting of all suspected adverse reactions to drugs and other medicinal substances including herbal, traditional or alternative remedies must be encouraged. The reporting of seemingly insignificant or common adverse reactions would be important since it may highlight a wide spread prescribing problem. The 5 regional centers covering north, east, central, west and south record ADR data locally, scrutinize the data received from peripheral centers, subject its data to causality assessment and report to its zonal center. The 2 zonal centers also generate their own ADR data, Pharmacovigilance center. All centers can report for National Pharmacovigilance center directly so that regulatory decisions can be taken promptly. The National Pharmacovigilance center then recommends the CDSCO for regulatory actions, including amendments to label and suspension or withdrawal of product. In last 2 decades many drugs have been withdrawn from market because of detection of serious adverse reactions during postmarketting surveillance. A very recent example is of rofecoxib, a selective COX2 inhibitor which has been banned due to severe cardiovascular side effects. The relevant information is then disseminated through ADR news bulletins, drug alerts and seminars.
But the success of the program rest on the shoulders of health professionals. To derive maximum benefit from the program it is important that all clinicians assume responsibility in reporting adverse drug reactions. ADR reporting form published by CDSCO and list of all peripheral, regional and zonal centers can be downloaded from website of CDSCO. (www.cdsco.nic.in) It maintains patient confidentiality. However identification of notifier is obligatory to allow for verification of information and to avoid submission of spurious data. To conclude spontaneous reporting of all suspected adverse drug events and ADRs by health professionals is the backbone. The practicing physicians should assume responsibility in reporting the observed ADRs to authorities, so that necessary preventive steps can be taken to protect our fellow beings from these avoidable risks associated with drug use.
Benefit of ADR monitoring and reporting

